-transparent.png){kind=logo}
We have investigated the efficacy of mitoxantrone in combination with etoposide in patients with refractory acute myelogenous leukemia. The regimen consisted of 10 mg/m2/day of mitoxantrone given iv on Days 1-5; and 100 mg/m2/day of etoposide as short infusion, initially on Days 1-3 and extended to Days 4 and 5 as appropriate. Of the 26 patients treated with this combination, nine (34.6%) have achieved complete remission and two have achieved partial remission. The median duration of continuous complete remission was 85 days (range, 21-183+). Toxicity was mild and only one case of early death was observed. This combination seems to be an active regimen in refractory acute myelogenous leukemia, and its incorporation in front-line therapy seems warranted.
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
January 1990,
Haematology and blood transfusion,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
November 1989,
European journal of haematology,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
November 2000,
Leukemia & lymphoma,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
January 1990,
Haematology and blood transfusion,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
December 2014,
Leukemia research,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
January 1990,
Haematology and blood transfusion,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
May 2000,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
February 2006,
Leukemia research,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
November 2016,
Leukemia & lymphoma,
A D Ho, and
T Lipp, and
G Ehninger, and
P Meyer, and
M Freund, and
W Hunstein
August 1988,
Cancer,
